nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—MAOA—conduct disorder	0.884	1	CbGaD
Phenylpropanolamine—MAOA—Enzymatic degradation of Dopamine by monoamine oxidase—COMT—conduct disorder	0.011	0.101	CbGpPWpGaD
Phenylpropanolamine—MAOA—Clearance of dopamine—COMT—conduct disorder	0.00794	0.0728	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Clearance of dopamine—COMT—conduct disorder	0.00738	0.0676	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Clearance of dopamine—MAOA—conduct disorder	0.00733	0.0671	CbGpPWpGaD
Phenylpropanolamine—DRD1—Dopamine receptors—DRD4—conduct disorder	0.00647	0.0593	CbGpPWpGaD
Phenylpropanolamine—MAOA—Serotonin Transporter Activity—SLC6A4—conduct disorder	0.0037	0.034	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.00362	0.0332	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.00337	0.0309	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—conduct disorder	0.00334	0.0306	CbGpPWpGaD
Phenylpropanolamine—MAOA—Dopamine metabolism—COMT—conduct disorder	0.00246	0.0225	CbGpPWpGaD
Phenylpropanolamine—MAOA—Biogenic Amine Synthesis—COMT—conduct disorder	0.00219	0.0201	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Monoamine Transport—SLC6A4—conduct disorder	0.00165	0.0152	CbGpPWpGaD
Phenylpropanolamine—DRD1—Hypothetical Network for Drug Addiction—DRD4—conduct disorder	0.00147	0.0134	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Monoamine Transport—SLC6A4—conduct disorder	0.00147	0.0134	CbGpPWpGaD
Phenylpropanolamine—DRD1—Monoamine GPCRs—DRD4—conduct disorder	0.00143	0.0131	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Monoamine GPCRs—DRD4—conduct disorder	0.00129	0.0118	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Monoamine GPCRs—DRD4—conduct disorder	0.00126	0.0115	CbGpPWpGaD
Phenylpropanolamine—Tranylcypromine—MAOA—conduct disorder	0.00124	0.173	CrCbGaD
Phenylpropanolamine—DRD1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0012	0.011	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Melatonin metabolism and effects—MAOA—conduct disorder	0.00114	0.0105	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Methylation—COMT—conduct disorder	0.00112	0.0102	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Amine ligand-binding receptors—DRD4—conduct disorder	0.00108	0.0099	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Amine ligand-binding receptors—DRD4—conduct disorder	0.00106	0.00969	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Monoamine GPCRs—DRD4—conduct disorder	0.00104	0.00953	CbGpPWpGaD
Phenylpropanolamine—Phentermine—MAOA—conduct disorder	0.00104	0.145	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—MAOA—conduct disorder	0.000986	0.138	CrCbGaD
Phenylpropanolamine—ADRA2A—Monoamine GPCRs—DRD4—conduct disorder	0.000966	0.00886	CbGpPWpGaD
Phenylpropanolamine—DRD1—Monoamine GPCRs—HTR2A—conduct disorder	0.000933	0.00855	CbGpPWpGaD
Phenylpropanolamine—DRD1—G alpha (s) signalling events—CGA—conduct disorder	0.000885	0.00811	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.000874	0.00801	CbGpPWpGaD
Phenylpropanolamine—Phenelzine—MAOA—conduct disorder	0.000848	0.118	CrCbGaD
Phenylpropanolamine—ADRB1—Monoamine GPCRs—HTR2A—conduct disorder	0.000839	0.00769	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Monoamine GPCRs—HTR2A—conduct disorder	0.00082	0.00752	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Amine ligand-binding receptors—DRD4—conduct disorder	0.000812	0.00744	CbGpPWpGaD
Phenylpropanolamine—ADRB1—G alpha (s) signalling events—CGA—conduct disorder	0.000796	0.00729	CbGpPWpGaD
Phenylpropanolamine—DRD1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000784	0.00719	CbGpPWpGaD
Phenylpropanolamine—ADRB2—G alpha (s) signalling events—CGA—conduct disorder	0.000779	0.00714	CbGpPWpGaD
Phenylpropanolamine—Methamphetamine—MAOA—conduct disorder	0.000741	0.104	CrCbGaD
Phenylpropanolamine—ADRB1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000705	0.00646	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.000698	0.0064	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00069	0.00632	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Monoamine GPCRs—HTR2A—conduct disorder	0.000679	0.00622	CbGpPWpGaD
Phenylpropanolamine—Phentermine—SLC6A4—conduct disorder	0.00067	0.0937	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A4—conduct disorder	0.000635	0.0888	CrCbGaD
Phenylpropanolamine—ADRA2A—Monoamine GPCRs—HTR2A—conduct disorder	0.00063	0.00578	CbGpPWpGaD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.000573	0.00525	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00057	0.00523	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Other—DRD4—conduct disorder	0.000558	0.00512	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.000533	0.00488	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00053	0.00486	CbGpPWpGaD
Phenylpropanolamine—Amphetamine—SLC6A4—conduct disorder	0.000515	0.0721	CrCbGaD
Phenylpropanolamine—SLC6A2—NRF2 pathway—SLC6A4—conduct disorder	0.000491	0.0045	CbGpPWpGaD
Phenylpropanolamine—Methamphetamine—SLC6A4—conduct disorder	0.000478	0.0668	CrCbGaD
Phenylpropanolamine—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.000473	0.00434	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000444	0.00407	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—GABRA2—conduct disorder	0.000439	0.00402	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—NRF2 pathway—SLC6A4—conduct disorder	0.000435	0.00399	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000422	0.00387	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—GABRA2—conduct disorder	0.000408	0.00374	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000379	0.00348	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000371	0.0034	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Other—HTR2A—conduct disorder	0.000364	0.00334	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—SLC6A4—conduct disorder	0.000358	0.00328	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—DRD4—conduct disorder	0.000337	0.00309	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—CGA—conduct disorder	0.000321	0.00295	CbGpPWpGaD
Phenylpropanolamine—MAOA—Biological oxidations—COMT—conduct disorder	0.000311	0.00285	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000307	0.00281	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—CGA—conduct disorder	0.000289	0.00265	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000285	0.00261	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—CGA—conduct disorder	0.000283	0.00259	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000276	0.00253	CbGpPWpGaD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—COMT—conduct disorder	0.000276	0.00253	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000272	0.0025	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—COMT—conduct disorder	0.000256	0.00235	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—MAOA—conduct disorder	0.000255	0.00233	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000248	0.00227	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000248	0.00227	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000243	0.00222	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000236	0.00217	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—CGA—conduct disorder	0.000234	0.00214	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000219	0.00201	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—CGA—conduct disorder	0.000217	0.00199	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000215	0.00197	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000213	0.00195	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—COMT—conduct disorder	0.000211	0.00194	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000208	0.00191	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—DRD4—conduct disorder	0.000201	0.00184	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000201	0.00184	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—COMT—conduct disorder	0.000196	0.0018	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.000196	0.0018	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—MAOA—conduct disorder	0.000195	0.00179	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000186	0.00171	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—CGA—conduct disorder	0.000182	0.00166	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00018	0.00165	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—DRD4—conduct disorder	0.00018	0.00165	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000172	0.00158	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—G alpha (q) signalling events—HTR2A—conduct disorder	0.000169	0.00155	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—CGA—conduct disorder	0.000165	0.00151	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—CGA—conduct disorder	0.000163	0.0015	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000162	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—DRD4—conduct disorder	0.000162	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00016	0.00146	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—CGA—conduct disorder	0.00016	0.00146	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000158	0.00145	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—DRD4—conduct disorder	0.000158	0.00145	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000154	0.00141	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000152	0.00139	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CGA—conduct disorder	0.000148	0.00136	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CGA—conduct disorder	0.000145	0.00133	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000144	0.00132	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000141	0.0013	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.000141	0.0013	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000139	0.00127	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000136	0.00124	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CGA—conduct disorder	0.000132	0.00121	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000131	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—DRD4—conduct disorder	0.000131	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CGA—conduct disorder	0.000123	0.00113	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000122	0.00112	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—DRD4—conduct disorder	0.000122	0.00112	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CGA—conduct disorder	0.00012	0.0011	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CGA—conduct disorder	0.000118	0.00108	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—HTR2A—conduct disorder	0.000117	0.00108	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—EP300—conduct disorder	0.000116	0.00107	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—COMT—conduct disorder	0.000115	0.00105	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.000114	0.00104	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.000113	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000112	0.00103	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CGA—conduct disorder	0.000111	0.00102	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—HTR2A—conduct disorder	0.000106	0.000968	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000104	0.000955	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—HTR2A—conduct disorder	0.000103	0.000947	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—DRD4—conduct disorder	0.000102	0.000932	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	9.76e-05	0.000895	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CGA—conduct disorder	9.74e-05	0.000893	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—DRD4—conduct disorder	9.24e-05	0.000847	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD4—conduct disorder	9.14e-05	0.000838	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD4—conduct disorder	8.95e-05	0.00082	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CGA—conduct disorder	8.76e-05	0.000803	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CGA—conduct disorder	8.57e-05	0.000785	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—HTR2A—conduct disorder	8.54e-05	0.000783	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD4—conduct disorder	8.3e-05	0.000761	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD4—conduct disorder	8.12e-05	0.000745	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—HTR2A—conduct disorder	7.94e-05	0.000728	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CGA—conduct disorder	7.88e-05	0.000722	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—WASF1—conduct disorder	7.81e-05	0.000716	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD4—conduct disorder	7.4e-05	0.000678	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CGA—conduct disorder	7.09e-05	0.00065	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—WASF1—conduct disorder	7.02e-05	0.000643	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD4—conduct disorder	6.88e-05	0.00063	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—WASF1—conduct disorder	6.87e-05	0.000629	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD4—conduct disorder	6.72e-05	0.000616	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—HTR2A—conduct disorder	6.64e-05	0.000608	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CGA—conduct disorder	6.59e-05	0.000604	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD4—conduct disorder	6.24e-05	0.000572	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HTR2A—conduct disorder	6.03e-05	0.000552	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—HTR2A—conduct disorder	5.97e-05	0.000547	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—HTR2A—conduct disorder	5.84e-05	0.000535	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—WASF1—conduct disorder	5.68e-05	0.000521	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD4—conduct disorder	5.46e-05	0.0005	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HTR2A—conduct disorder	5.42e-05	0.000497	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—COMT—conduct disorder	5.32e-05	0.000488	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HTR2A—conduct disorder	5.3e-05	0.000486	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—WASF1—conduct disorder	5.28e-05	0.000484	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD4—conduct disorder	4.91e-05	0.00045	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HTR2A—conduct disorder	4.83e-05	0.000442	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD4—conduct disorder	4.8e-05	0.00044	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR2A—conduct disorder	4.49e-05	0.000411	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR2A—conduct disorder	4.38e-05	0.000402	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CGA—conduct disorder	4.35e-05	0.000398	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR2A—conduct disorder	4.07e-05	0.000373	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD4—conduct disorder	3.97e-05	0.000364	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—EP300—conduct disorder	3.76e-05	0.000345	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD4—conduct disorder	3.69e-05	0.000338	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2A—conduct disorder	3.56e-05	0.000326	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—COMT—conduct disorder	3.56e-05	0.000326	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MAOA—conduct disorder	3.53e-05	0.000324	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2A—conduct disorder	3.2e-05	0.000293	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2A—conduct disorder	3.13e-05	0.000287	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—conduct disorder	2.59e-05	0.000237	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—conduct disorder	2.41e-05	0.000221	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—EP300—conduct disorder	2.28e-05	0.000209	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—COMT—conduct disorder	1.96e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MAOA—conduct disorder	1.95e-05	0.000179	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	1.89e-05	0.000173	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EP300—conduct disorder	1.89e-05	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EP300—conduct disorder	1.7e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EP300—conduct disorder	1.66e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—EP300—conduct disorder	1.52e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EP300—conduct disorder	1.37e-05	0.000126	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EP300—conduct disorder	1.27e-05	0.000117	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—EP300—conduct disorder	8.42e-06	7.71e-05	CbGpPWpGaD
